Adaptimmune Therapeutics (ADAP) Short Interest Ratio & Short Volume → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free ADAP Stock Alerts $1.58 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Adaptimmune Therapeutics Short Interest DataCurrent Short Volume3,110,000 sharesPrevious Short Volume2,800,000 sharesChange Vs. Previous Month+11.07%Dollar Volume Sold Short$4.60 millionShort Interest Ratio / Days to Cover1.7Last Record DateMarch 15, 2024Outstanding Shares994,210,000 sharesPercentage of Shares Shorted0.31%Today's Trading Volume1,066,310 sharesAverage Trading Volume1,889,894 sharesToday's Volume Vs. Average56% Short Selling Adaptimmune Therapeutics ? Sign up to receive the latest short interest report for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatADAP Short Interest Over TimeADAP Days to Cover Over TimeADAP Percentage of Float Shorted Over Time Ad Crypto 101 MediaTop Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. Adaptimmune Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20243,110,000 shares $4.60 million +11.1%N/A1.7 $1.48 2/29/20242,800,000 shares $4.40 million -4.4%N/A1.6 $1.57 2/15/20242,930,000 shares $3.66 million -37.8%N/A2.1 $1.25 1/31/20244,710,000 shares $4.52 million -18.4%N/A3.8 $0.96 1/15/20245,770,000 shares $4.75 million +1.2%N/A9.3 $0.82 12/31/20235,700,000 shares $4.52 million -6.9%N/A9.6 $0.79 Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/20236,120,000 shares $2.75 million -0.8%N/A12 $0.45 11/30/20236,170,000 shares $3.09 million +3.0%N/A14.4 $0.50 11/15/20235,990,000 shares $3.00 million +2.4%N/A14.3 $0.50 10/31/20235,850,000 shares $3.16 million -12.6%N/A14.2 $0.54 10/15/20236,690,000 shares $4.39 million +12.1%N/A14.7 $0.66 9/30/20235,970,000 shares $4.66 million -1.3%N/A12.2 $0.78 9/15/20236,050,000 shares $4.91 million +3.1%N/A10.3 $0.81 8/31/20235,870,000 shares $4.58 million +1.9%N/A8.3 $0.78 8/15/20235,760,000 shares $4.49 million +0.4%N/A6.5 $0.78 7/31/20235,740,000 shares $5.41 million +1.4%3.9%6.5 $0.94 7/15/20235,660,000 shares $5.10 million -5.5%3.8%6.2 $0.90 6/30/20235,990,000 shares $5.54 million -19.6%4.1%6.3 $0.93 6/15/20237,450,000 shares $7.52 million -25.2%5.1%8.4 $1.01 5/31/20239,960,000 shares $10.16 million +8.7%6.8%11.6 $1.02 5/15/20239,160,000 shares $12.73 million +2.0%6.2%12.1 $1.39 4/30/20238,980,000 shares $12.75 million +19.9%6.2%12.5 $1.42 4/15/20237,490,000 shares $10.19 million +11.3%5.1%11.6 $1.36 3/31/20236,730,000 shares $7.34 million +28.7%4.6%11.9 $1.09 3/15/20235,230,000 shares $5.91 million +81.0%3.6%9.6 $1.13 2/28/20232,890,000 shares $5.12 million +1.8%2.0%6.5 $1.77 2/15/20232,840,000 shares $4.69 million +1.4%2.0%8.4 $1.65 1/31/20232,800,000 shares $5.24 million +3.3%1.9%6.4 $1.87 1/15/20232,710,000 shares $5.07 million -8.1%1.9%5.1 $1.87 12/30/20222,950,000 shares $4.31 million +7.7%2.0%5.6 $1.46 12/15/20222,740,000 shares $3.73 million -1.4%1.9%5.3 $1.36 11/30/20222,780,000 shares $6.03 million -26.1%1.9%5.3 $2.17 11/15/20223,760,000 shares $8.95 million +12.6%2.6%7.6 $2.38 10/31/20223,340,000 shares $4.74 million -10.0%2.3%7.9 $1.42 10/15/20223,710,000 shares $4.19 million -6.6%2.6%9.3 $1.13 9/30/20223,970,000 shares $4.27 million +7.0%2.8%13.5 $1.08 9/15/20223,710,000 shares $6.01 million +0.3%2.6%12.3 $1.62 8/31/20223,700,000 shares $7.33 million +1.7%2.6%11.6 $1.98 8/15/20223,640,000 shares $8.77 million -2.2%2.5%10.6 $2.41 7/31/20223,720,000 shares $6.88 million -7.9%2.6%9.7 $1.85Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024. ADAP Short Interest - Frequently Asked Questions What is Adaptimmune Therapeutics' current short interest? Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 3,110,000 shares of ADAP short. Learn More on Adaptimmune Therapeutics' current short interest. What is a good short interest ratio for Adaptimmune Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADAP shares currently have a short interest ratio of 2.0. Learn More on Adaptimmune Therapeutics's short interest ratio. Which institutional investors are shorting Adaptimmune Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Adaptimmune Therapeutics: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Adaptimmune Therapeutics' short interest increasing or decreasing? Adaptimmune Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 3,110,000 shares, an increase of 11.1% from the previous total of 2,800,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptimmune Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Adaptimmune Therapeutics: ADMA Biologics, Inc. (3.50%), Autolus Therapeutics plc (1.36%), Inhibrx, Inc. (4.50%), Vir Biotechnology, Inc. (6.17%), 4D Molecular Therapeutics, Inc. (17.08%), Fusion Pharmaceuticals Inc. (9.35%), Scholar Rock Holding Co. (13.54%), Tarsus Pharmaceuticals, Inc. (21.04%), Twist Bioscience Co. (20.77%), BioCryst Pharmaceuticals, Inc. (14.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Adaptimmune Therapeutics stock? Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptimmune Therapeutics? A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further. How often is Adaptimmune Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: ADMA Short Interest Data AUTL Short Interest Data INBX Short Interest Data VIR Short Interest Data FDMT Short Interest Data FUSN Short Interest Data SRRK Short Interest Data TARS Short Interest Data TWST Short Interest Data BCRX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADAP) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets